- C
Cytimmune Sciences
- Giulio Paciotti, Ph.D.
Giulio Paciotti, Ph.D. has over 35 years of experience in the field of nanotechnology and medical research. Giulio is currently the Chief Science Officer at Cytimmune Sciences, where they lead the company's R&D and manufacturing efforts. Dr. Paciotti has won multiple grants for their work and has led the development of several therapeutics entering clinical trials. Prior to joining Cytimmune Sciences, they worked as a Consultant/Vice President of Research and Development at Otomagnetics, Inc. from 2018 to 2020. Before that, Dr. Paciotti served as the Vice President of Research and Development at Imagion Biosystems, Inc. from 2016 to 2018, where they led the development of the company's MagSense In Vivo Diagnostic Platform. Giulio was responsible for identifying fundamental characteristics of nanoparticles, generating novel surface chemistries, and establishing analytical programs. Dr. Paciotti also has a long history with CytImmune Sciences, having served as the Chief Science Officer from 1999 to 2016. During their tenure, they spearheaded the development of nanotechnology therapeutic programs and secured significant funding. Additionally, they worked as the Vice President of Research and Development at Assay Research, Inc. from 1988 to 1999, where they patented a research diagnostic technology and initiated R&D on drug delivery using nanoparticles. Dr. Paciotti began their career as a Biologist at the National Institutes of Health in 1985, where their research in immunology and oncology laid the foundation for their future work.
Giulio Paciotti, Ph.D. obtained a Bachelor's Degree in Zoology/Animal Biology from the University of Maryland in 1982. Following this achievement, they pursued a Master's Degree in Cell Biology and Physiology from the same institution, which they completed in 1984. Giulio continued their studies at the University of Maryland and earned a Ph.D. in Cancer Cell Biology in 1994.
Org chart
Teams
This person is not in any teams
Offices
Cytimmune Sciences
CytImmune Sciences, Inc. created a first-in-class, patented nanomedicine platform, Aurimune™. All Aurimune products seek out and destroy the blood vessels inside any primary or metastatic solid tumor. Tumor blood vessel destruction alters the tumor microenvironment in a way that significantly improves the effectiveness of other therapies includingchemotherapies, radiation therapies and immunotherapies. CYT-6091, the first generation Aurimune nanomedicine and a first-in-class therapeutic, was shown to be safe and tumor-targeted in a Phase I Clinical Trial. CytImmune is raising funds to advance CYT-6091 through Clinical Trials. All Aurimune™ products are built around a 27nm gold nanoparticle core. Gold is known to be safe, has a flexible chemistry including forming covalent bonds, and can be manufactured with scale and precision in GMP conditions. All Aurimune products carry Tumor Necrosis Factor Alpha (TNF). Additionally, CytImmune developed a patented gold pegylation technology to prevent Aurimune removal by the immune system. This stealth attribute allows Aurimune to remain in circulation long enough to concentrate inside solid tumors. The Aurimune family of nanomedicines includes CYT-6091 and several second generation, multifunctional nanomedicines. Second generation nanomedicines use TNF to destroy tumor blood vessels, then deliver anti-cancer agents including chemotherapies and targeted biologics into the tumor. Preclinical data indicate this approach concentrates anti-cancer therapies inside solid tumors, which dramatically increases effectiveness while reducing drug-related side effects. Therapeutics delivered by second generation Aurimune products include:•Common Small Molecule Chemotherapies: Paclitaxel, Doxorubicin, Gemcitabine•Targeted Therapies and Biologics: TNF, Interferon Gamma, Mono and Bi-valent SMAC Memetics
